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AbsTrACT
Objectives high-sensitivity cardiac troponin testing 
is used in the diagnosis of acute coronary syndromes 
but its role during convalescence is unknown. We 
investigated the long-term prognostic significance of 
serial convalescent high-sensitivity cardiac troponin 
concentrations following acute coronary syndrome.
Methods in a prospective multicentre observational 
cohort study of 2140 patients with acute coronary 
syndrome, cardiac troponin i concentrations were 
measured in 1776 patients at 4 and 12 months following 
the index event. Patients were stratified into three groups 
according to the troponin concentration at 4 months 
using the 99th centile (women>16 ng/l, men>34 ng/l) 
and median concentration of those within the reference 
range. the primary outcome was cardiovascular death.
results troponin concentrations at 4 months were 
measurable in 99.0% (1759/1776) of patients (67±12 
years, 72% male), and were ≤5 ng/l (median) and >99th 
centile in 44.8% (795) and 9.3% (166), respectively. 
there were 202 (11.4%) cardiovascular deaths after 
a median of 4.8 years. after adjusting for the global 
registry of acute coronary events score, troponin 
remained an independent predictor of cardiovascular 
death (hr 1.4, 95% ci 1.3 to 1.5 per doubling) with 
the highest risk observed in those with increasing 
concentrations at 12 months. Patients with 4-month 
troponin concentrations >99th centile were at increased 
risk of cardiovascular death compared with those 
≤5 ng/l (29.5% (49/166) vs 4.3% (34/795); adjusted hr 
4.9, 95% ci 3.8 to 23.7).
Conclusions convalescent cardiac troponin 
concentrations predict long-term cardiovascular death 
following acute coronary syndrome. recognising this 
risk by monitoring troponin may improve targeting of 
therapeutic interventions.
Trial registration number actrn12605000431628; 
results.
InTrOduCTIOn
In the assessment of patients with suspected acute 
coronary syndrome, international guidelines recom-
mend serial measurement of cardiac troponin in 
accordance with the universal definition of myocar-
dial infarction.1 In this acute context, increased 
troponin concentrations above the 99th centile 
reference limit have consistently demonstrated a 
correlation between infarct size and subsequent 
prognosis.2 Recently approved high-sensitivity 
troponin assays have also revealed a gradient of risk 
associated with concentrations below the diagnostic 
threshold at the time of initial presentation.3–5 
However, no guidance is offered on measuring 
troponin once a diagnosis is established, and long-
term risk stratification following hospital discharge 
is largely dependent on left ventricular function and 
the presence of residual inducible ischaemia.6 
Despite the widely accepted view that troponin 
concentrations typically return to baseline levels 
within 2 weeks, the exact time course of resolution 
of cardiac troponin following myocardial infarction 
remains unclear and several reports have described 
persistent elevations up to 7 weeks following initial 
presentation.7 8 Plausible contributory mechanisms 
include delayed healing of the ruptured plaque, 
persistent left ventricular dysfunction or asymp-
tomatic ischaemia.8 9
There is now emerging evidence from posthoc 
analysis of clinical trial populations that increased 
troponin concentrations during the early and inter-
mediate postmyocardial infarction period confer 
greater risk of recurrent cardiovascular events.10 11 
However, the time course and clinical implications 
of persistent myocardial injury following acute 
coronary syndrome remain uncertain. We sought to 
determine the long-term prognostic significance of 
serial convalescent high-sensitivity cardiac troponin 
I concentrations in a large prospective study incor-
porating detailed clinical characterisation following 
acute coronary syndrome.
MeThOds
study population
From 2002 to 2009, 2140 patients were enrolled 
into the Coronary Disease Cohort Study (CDCS), 
a prospective, multicentre (Christchurch and Auck-
land City Hospitals) observational cohort study 
in New Zealand designed to explore the determi-
nants of long-term risk following acute coronary 
syndrome.12 Inclusion required hospitalisation with 
an acute coronary syndrome diagnosed according 
to previously reported criteria (online supple-
mentary appendix).13 The CDCS conforms to the 
principles outlined in the Declaration of Helsinki 
and was approved by the New Zealand Multi-Re-
gion Ethics Committee. All participants provided 
written, informed consent.
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Clinical assessments and outcomes
Patients underwent comprehensive clinical assessment including 
a 12-lead ECG, echocardiography and blood sampling at 1, 
4 and 12 months following the index event, with additional 
annual review for at least 2 years (online supplementary table 
S1). Echocardiographic assessment was performed according 
to the recommendations of the American Society of Echocar-
diography.14 Long-term clinical events (hospitalisations and 
mortality) were determined from the New Zealand National 
Health Information Services databases, comprising comprehen-
sive population-wide records linked by a unique identifier. All 
deaths were adjudicated for cause by a cardiologist blind to study 
troponin measurements. Further details regarding endpoint clas-
sification are provided in the online supplementary appendix.
biomarker analysis
Following collection and centrifugation, EDTA-plasma blood 
samples were stored at −80°C until analysed. High-sensitivity 
cardiac troponin I concentrations were determined using the 
ARCHITECTSTAT assay (Abbott Laboratories, Abbott Park, Illi-
nois, USA), which has a limit of detection of 1.2 ng/L, coefficient 
of variation <10% at 3.0 ng/L and 99th centile upper reference 
limit of 16 ng/L for women and 34 ng/L for men.15 16 To allow 
for variation in hospital stay and ensure resolution of the initial 
ischaemic event, the convalescent troponin concentration was 
defined as that obtained at the second study visit at 4 months. 
For the purposes of this analysis, patients were excluded if they 
had experienced a recurrent myocardial infarction prior to this 
visit (n=201) or failed to attend (n=79) or have a troponin 
measurement performed (n=84) at the 4-month visit (figure 1).
Clinical endpoints
The primary endpoint was cardiovascular death following the 
4-month visit. Secondary endpoints included all-cause death, 
non-cardiovascular death, fatal or non-fatal myocardial infarc-
tion, heart failure hospitalisation, the composite of cardiovas-
cular death or non-fatal myocardial infarction and hospitalisation 
with non-fatal stroke.
statistical analysis
Patient characteristics were reported by groups determined from 
the 4-month troponin concentration rounded to the nearest 
integer value. Groups 1 and 2 comprised those below and above 
the median troponin concentration excluding those in group 3 
with concentrations above the sex-specific 99th centiles. Cox 
regression results are reported as HRs per doubling of troponin 
concentration, both unadjusted and following adjustment for the 
Global Registry of Acute Coronary Events (GRACE) risk score at 
time of discharge following index hospitalisation.17
In determining the relationship between troponin concen-
trations and treatment, we defined optimal medical therapy at 
discharge as per current clinical guidelines.18
Clinical determinants of cardiac troponin concentrations were 
determined from linear mixed models. The slope (time since 
initial presentation) and intercept were included as random 
effects. Time varying covariates were centred within-person as 
per Curran and Bauer.19 In a sensitivity analysis, we repeated the 
modelling with time as a categorical variable, using an unstruc-
tured correlation matrix for the within-person errors.
The negative predictive values for the primary outcome were 
established across a range of troponin concentrations starting at 
2 ng/L with a negative predictive value at 5 years of 97.5% eval-
uated as an acceptable threshold indicator of low risk.20
In a landmark analysis following the 12-month visit, the addi-
tional prognostic information provided by serial changes in 
troponin concentration was determined by including 12-month 
troponin concentrations in a Cox proportional hazards model 
adjusting for 4-month troponin concentrations. Patients were 
included in this analysis if they had troponin results available 
from all three study visits and had not experienced a recurrent 
myocardial infarction prior to the 12-month visit (n=1513).
Data are presented as mean (±SD) or median (IQR) with 
95% CI with two-tailed p values reported. Statistical analysis 
was performed using R V.3.4.3 (R Foundation for Statistical 
Computing, Vienna, Austria). Additional details of the statistical 
analyses undertaken are described in the online supplementary 
appendix.
resulTs
After excluding patients with recurrent myocardial infarction 
prior to the 4-month visit, 1776 patients (66.4±12.0 years, 
72% male) had troponin concentrations measured at the second 
study visit (128 (IQR 116–140) days) and were included in the 
analysis (table 1). The average duration of follow-up after the 
Figure 1 Study profile.
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Table 1 Baseline characteristics of patients with acute coronary syndrome stratified by cardiac troponin I concentration at 4 months
Total CdCs biomarker cohort ≤5 ng/l 6 ng/l–99th centile >99th centile
n 2140 1776 795 815 166
Age, years 66.5 (12.3) 66.4 (12.0) 63.7 (11.4) 68.2 (11.9) 70.8 (12.9)
Sex, male 1531 (71.5) 1282 (72.2) 534 (67.2) 661 (81.1) 87 (52.4)
Past medical history*
  Hypertension 1104 (52.0) 905 (51.4) 365 (46.4) 432 (53.5) 108 (65.1)
  Hypercholesterolaemia 1135 (54.3) 952 (54.5) 440 (56.1) 426 (53.2) 86 (53.1)
  Diabetes mellitus 353 (16.5) 276 (15.6) 96 (12.1) 142 (17.4) 38 (22.9)
  Smoking status
  Never smoked 787 (36.8) 669 (37.7) 290 (36.5) 316 (38.8) 63 (38.0)
  Ex-smoker 1218 (56.9) 999 (56.2) 448 (56.4) 465 (57.1) 86 (51.8)
  Current smoker 135 (6.3) 108 (6.1) 57 (7.2) 34 (4.2) 17 (10.2)
  Prior myocardial infarction 635 (29.9) 504 (28.5) 168 (21.2) 268 (33.0) 68 (41.5)
  Prior stroke 257 (12.1) 200 (11.3) 66 (8.3) 103 (12.7) 31 (18.7)
  Prior congestive heart failure 201 (9.4) 154 (8.7) 27 (3.4) 95 (11.7) 32 (19.5)
Status at presentation
  Heart rate, bpm 73.1 (20.3) 72.7 (20.6) 70.7 (19.3) 73.0 (20.8) 81.2 (23.2)
  Systolic blood pressure, mm Hg 134.9 (20.3) 135.3 (20.6) 135.1 (20.0) 133.4 (21.2) 148.3 (20.3)
  Killip class
  I 1577 (73.8) 1329 (75.0) 664 (83.7) 569 (69.9) 96 (57.8)
  II 526 (24.6) 419 (23.6) 124 (15.6) 233 (28.6) 62 (37.3)
  III/IV 33 (1.5) 25 (1.4) 5 (0.6) 12 (1.5) 8 (4.8)
  eGFR, mL/min 65.6 (19.9) 66.1 (19.5) 71.5 (16.9) 62.9 (20.1) 55.5 (20.5)
  ST depression 471 (22.1) 386 (21.9) 112 (14.1) 218 (26.9) 56 (33.9)
Positive cardiac biomarker (index admission) 1740 (81.4) 1422 (80.1) 575 (72.3) 691 (84.9) 156 (94.0)
No. of diseased vessels†
  0 105 (6.4) 90 (6.5) 63 (9.4) 21 (3.4) 6 (5.8)
  1 450 (27.5) 387 (27.8) 206 (30.7) 155 (25.0) 26 (25.2)
  2 487 (29.7) 413 (29.6) 194 (29.0) 187 (30.2) 32 (31.1)
  3 596 (36.4) 503 (36.1) 207 (30.9) 257 (41.5) 39 (37.9)
In-hospital percutaneous coronary intervention 1080 (50.5) 932 (52.5) 442 (55.6) 427 (52.4) 63 (38.0)
LVEF at 4 months, % 59.0 (52.0, 65.0) 61.0 (56.0, 66.0) 58.0 (49.0, 64.0) 51.0 (40.0, 61.0)
Medications at discharge
  Aspirin 2087 (97.6) 1736 (97.9) 781 (98.4) 798 (98.0) 157 (94.6)
  Clopidogrel 1244 (58.2) 1053 (59.4) 489 (61.6) 479 (58.8) 85 (51.2)
  Renin-angiotensin system-blocking agents‡ 1334 (62.4) 1095 (61.7) 419 (52.8) 553 (67.9) 123 (74.1)
  Beta-blocker 1856 (86.7) 1554 (87.5) 706 (88.8) 710 (87.1) 138 (83.1)
  Statin 1948 (91.1) 1623 (91.5) 743 (93.6) 739 (90.8) 141 (84.9)
Optimal medical therapy at discharge¶ 884 (49.8) 411 (51.7) 406 (49.8) 67 (40.4)
Index diagnosis
  Unstable angina 567 (26.5) 495 (27.9) 294 (37.0) 177 (21.7) 24 (14.5)
  NSTEMI 1089 (50.9) 864 (48.6) 377 (47.4) 388 (47.6) 99 (59.6)
  STEMI 484 (22.6) 417 (23.5) 124 (15.6) 250 (30.7) 43 (25.9)
Time from index admission to 4-month visit, 
days
128.0 (116.0, 140.0) 128.0 (116.0, 140.0) 129.0 (117.0, 142.0) 126.0 (115.0, 138.0) 128.0 (117.0, 141.8)
GRACE score 111.0 (31.7) 109.9 (30.8) 99.4 (25.2) 116.2 (30.9) 129.9 (36.2)
GRACE score tertile¶
  Low 614 (30.6) 517 (31.0) 286 (38.1) 204 (26.6) 27 (17.8)
  Intermediate 675 (33.7) 588 (35.2) 311 (41.5) 240 (31.2) 37 (24.3)
  High 716 (35.7) 565 (33.8) 153 (20.4) 324 (42.2) 88 (57.9)
*See https://www.outcomes-umassmed.org/grace/grace_risk_table.aspx).
†Determined at time of index hospital admission.
‡Determines from diagnostic coronary angiography performed during index admission.
§Including ACE inhibitors or angiotensin receptor blockers.
¶GRACE score tertiles determined according to index diagnosis: NSTEACS, low<88, intermediate 89–118, high≥119; STEMI, low<99, intermediate 100–127, high≥128.
§Optimal medical therapy defined as a prescription for all of aspirin, clopidogrel and a statin. In addition, prescription of a beta-blocker was required if the LVEF was ≤40%. An 
ACE inhibitor or angiotensin receptor blocker was also required if the LVEF was ≤40% or the patient had a diagnosis of hypertension or diabetes mellitus.
CDCS, Coronary Disease Cohort Study; eGFR, estimated glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; LVEF, left ventricular ejection 
fraction; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
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4-month visit was 4.8 years with a maximum follow-up of 9.2 
years. Patients had a substantial burden of cardiovascular risk 
factors including hypertension (51%), hypercholesterolaemia 
(55%) and diabetes mellitus (16%). The average estimated risk 
of death at 6 months as determined from the discharge GRACE 
score19 was 5.2%±0.8%.
distribution and trends in convalescent troponin 
concentrations
Median troponin concentrations declined at each successive visit 
over the first year with median values of 8.2 (IQR 4.2–17.8) ng/L, 
6.1 (IQR 3.6–11.5) ng/L and 4.8 (IQR 2.9–8.6) ng/L at the 
1-month, 4-month and 12-month visits, respectively (p<0.0001; 
figure 2). The proportion of patients with troponin concentra-
tions above the sex-specific 99th centile was 16.0% (1-month 
visit), 9.3% (4-month visit) and 5.9% (12-month visit).
At the 4-month visit, plasma troponin I concentrations were 
above the limit of detection and the sex-specific 99th centile 
threshold in 1759 (99.0%) and 166 (9.3%) patients, respectively 
(online supplementary figure S1). The median troponin concen-
tration of those within the reference range at the 4-month visit 
was 5.5 (women 4.0, men 6.0) ng/L. The extent of myocardial 
injury during the index admission (as determined by the peak 
creatine kinase concentration) was only weakly associated with 
troponin concentration at 4 months (r=0.19, p<0.0001). In 
contrast, troponin measured at 4 and 12 months were much more 
strongly correlated (r=0.78, p<0.0001; online supplementary 
figure S2). After adjustment for age, sex and left ventricular ejec-
tion fraction (LVEF), 4-month troponin was not associated with 
a change in prescription of optimal medical therapy (OR 0.99 
per doubling of troponin, 95% CI 0.92 to 1.08, p=0.8741), with 
49.7% receiving optimal medical therapy.
Convalescent troponin and cardiovascular outcomes
During follow-up, there were 375 deaths of which 202 were 
secondary to cardiovascular causes. A threshold of ≤5 ng/L 
applied at 4 months identified 45% of the study cohort (53% 
of women, 42% of men) with a negative predictive value for 
cardiovascular death at 5 years of 97.1% (95% CI 95.5 to 98.6; 
online supplementary figure S3) among both women and men. 
The negative predictive value decreased at higher troponin 
concentrations and was <97% at concentrations of ≥6 ng/L. In 
the prediction of this endpoint, the c-statistic for convalescent 
troponin (0.745, 95% CI 0.707 to 0.745) was greater than that 
provided by knowledge of the extent of myocardial injury during 
the index event as determined from peak concentrations during 
the index admission of either creatine kinase (c-statistic 0.562, 
95% CI 0.513 to 0.562), troponin I (c-statistic 0.585, 95% CI 
0.519 to 0.585) or troponin T (c-statistic 0.557, 95% I 0.504 
to 0.557; p<0.001 for all comparisons with 4 month troponin, 
online supplementary figure S4). This was also greater than the 
predictive value of LVEF as determined at the 4-month visit 
(c-statistic 0.679, 95% CI 0.621 to 0.738, p=0.0094). In unad-
justed analysis, 4-month troponin concentrations demonstrated 
a robust association with cardiovascular death (HR 1.50, 95% CI 
1.42 to 1.59 per doubling of troponin; p<0.0001, online supple-
mentary figure S5). This association remained after adjusting for 
the discharge GRACE score (HR 1.36, 95% CI 1.26 to 1.47 per 
doubling; p<0.0001) or an extended risk model incorporating 
additional clinical, biochemical and echocardiographic factors 
during follow-up to 4 months (HR 1.35, 95% CI 1.15 to 1.58; 
p=0.0002, online supplementary table S2). After adjustment for 
the discharge GRACE score, patients with convalescent troponin 
concentrations above the 99th centile had a fivefold increased 
risk of cardiovascular death compared with those ≤5 ng/L (HR 
4.87; 95% CI 2.96 to 7.99, p<0.0001, figure 3). The associa-
tion between troponin and secondary endpoints was greatest for 
cardiac events but remained for all-cause death and non-cardio-
vascular death (table 2).
serial measurement of troponin and cardiovascular outcomes
In a landmark analysis restricted to events following the 
12-month visit, troponin concentrations at the 12-month visit 
provided additional information regarding the risk of cardiovas-
cular death over and above the 4-month troponin concentration 
(p-interaction=0.0200; online supplementary table S3). The 
majority of patients (46.9%) demonstrated a ≥20% decline in 
troponin concentrations during this time period while in 16.1% 
of cases the troponin concentration increased by at least 20%. 
Increasing or decreasing troponin concentrations from 4 to 12 
months were associated with rising or falling risks of cardiovas-
cular death in all three groups although the absolute 5-year risk 
remained <10% in those ≤5 ng/L and >25% in those >99th 
centile at the 4-month visit (figure 4).
Clinical determinants of cardiac troponin in convalescence
Older patients had higher troponin concentrations at 4 months 
(1.25-fold difference per SD in age; 95% CI 1.19 to 1.30) and 
experienced a slower decline in troponin (1.18-fold difference 
per SD in age; 95% CI 1.13 to 1.23, online supplementary figure 
S6). While men had higher troponin concentrations than women 
(6.6 (IQR 3.8–12.0) ng/L vs 5.1 (IQR 3.0–9.7) ng/L; p<0.0001), 
the rate of decline was similar in both sexes. In age, sex and 
diagnosis-adjusted models, troponin was higher in patients with 
lower LVEF (0.74-fold difference per SD in ejection fraction; 
95% CI 0.71 to 0.77) and higher heart rates (1.08-fold differ-
ence per SD in heart rate; 95% CI 1.02 to 1.13). Within-patient 
decrease in LVEF and increase in systolic blood pressure and 
Figure 2 Trends in troponin concentration over 1 year following acute 
coronary syndrome. Patients with samples available at all time-points 
and without recurrent myocardial infarction prior to the 12-month visit 
were included in this analysis (n=1513). Each individual is represented 
as a circle coloured according to their troponin concentration at the 
1-month study visit. This demonstrates both average and individual 
change in troponin concentrations over time. The whiskers of the 
boxplots extend to the highest or lowest values not greater than 1.5 
times the IQR of troponin concentrations.
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heart rate were also associated with increase in troponin from 4 
to 12 months (online supplementary table S4).
dIsCussIOn
In the evaluation of patients following hospitalisation with 
acute coronary syndrome, convalescent high-sensitivity cardiac 
troponin conveys powerful long-term prognostic information 
that adds substantially to currently recognised clinical risk 
predictors and scores. Indeed, even after adjustment for the 
GRACE score, we identified a fivefold increase in risk of cardio-
vascular death, associated with increasing convalescent troponin 
concentrations. This gradient of risk was continuous across the 
range of troponin concentrations and was greatest for cardiac 
events including cardiac death and heart failure hospitalisation.
Our study has several important strengths. First, the avail-
ability of comprehensive outcome data with more than 200 
cardiovascular deaths during up to 9 years of follow-up is a 
major asset and enabled us to define the long-term prognostic 
significance of convalescent measurement of troponin. Second, 
the deliberately broad inclusion criteria ensured recruitment of 
a diverse and representative cohort of real-world patients with 
acute coronary syndrome. The even distribution of patients 
across low-risk, intermediate-risk and high-risk groups as deter-
mined by the GRACE risk score offers strong evidence as to the 
generalisability of our findings. Third, detailed characterisa-
tion with repeated clinical, biochemical and echocardiographic 
assessments at three time points allowed us to explore patterns 
of change in convalescent troponin concentrations, and how 
these correlate with both patient characteristics and long-term 
outcomes.
Our findings have clear potential to improve follow-up 
and management of patients discharged following acute coro-
nary syndrome. We have shown that a single measurement of 
cardiac troponin during convalescence from an acute coronary 
Figure 3 Cumulative incidence of cardiovascular death according to 4-month troponin concentration Cumulative event curves for cardiovascular 
death according to troponin concentrations determined at the 4-month visit. Each cross-hair indicates when a subject is censored from further follow-
up. The number at risk (% in group remaining) for each yearly interval is given for each troponin group. Follow-up begins from date of 4-month visit. 
*For descriptive purposes, troponin concentrations have been rounded to nearest integer value. Therefore ≤5 ng/L includes all patients <5.5 ng/L.
Table 2 Cox proportional hazards for secondary endpoints according to troponin adjusted for GRACE discharge risk
≤5 ng/l 6 ng/l–99th centile >99th centile*
(n=795) (n=815) hr (95% CI) (n=166) hr (95% CI)
Cardiovascular death 34 (4.3) 119 (14.6) 2.52 (1.65 to 3.85) 49 (29.5) 4.87 (2.96 to 7.99)
Cardiac death 25 (3.1) 92 (11.3) 2.51 (1.54 to 4.07) 43 (25.9) 5.50 (3.17 to 9.57)
All-cause death 81 (10.2) 216 (26.5) 1.90 (1.44 to 2.51) 78 (47.0) 3.34 (2.36 to 4.73)
Cardiovascular death or non-fatal myocardial 
infarction
123 (15.5) 236 (29.0) 1.58 (1.25 to 2.01) 74 (44.6) 2.51 (1.82 to 3.44)
Non-cardiovascular death 47 (5.9) 97 (11.9) 1.48 (1.02 to 2.16) 29 (17.5) 2.30 (1.38 to 3.81)
Fatal or non-fatal myocardial infarction 102 (12.8) 168 (20.6) 1.38 (1.06 to 1.80) 53 (31.9) 2.23 (1.55 to 3.21)
Heart failure hospitalisation 53 (6.7) 165 (20.2) 2.09 (1.48 to 2.95) 66 (39.8) 3.98 (2.62 to 6.05)
Non-fatal stroke 45 (5.7) 68 (8.3) 1.12 (0.73 to 1.71) 13 (7.8) 0.98 (0.48 to 2.02)
*99th centile determined using sex-specific cut points (women>16 ng/L, men>34 ng/L).
Values are n (%) unless otherwise stated.
GRACE, Global Registry of Acute Coronary Events.
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syndrome can identify nearly half of patients as low-risk, with 
0.5% annual incidence of cardiovascular death. A further 1 in 
10 patients have persistent myocardial injury and are identified 
as very high risk, with annual event rates approaching 10%, for 
whom careful assessment and more intensive treatment may be 
warranted. Furthermore, we have demonstrated that for those 
at intermediate risk, repeated measurement of cardiac troponin 
concentrations at 12 months can be used to improve risk estima-
tion and enable prognostic reclassification into either low-risk or 
high-risk groups.
Convalescent troponin concentrations are not simply a surro-
gate for the extent of myocardial injury sustained during the 
index coronary event as evidenced by the weak correlation 
between peak troponin during the index hospitalisation and 
4-month troponin. Neither are they simply a reflection of left 
ventricular function. Instead, they provide greater prognostic 
information than either of these traditional risk indicators and 
are additive to all other clinical, biochemical and echocardio-
graphic risk factors that might typically be available to clinicians 
when making treatment decisions. Furthermore, within this 
real-world observational study, we have revealed a substantial 
treatment gap whereby less than half of patients with troponin 
concentrations >99th centile received all guideline-indicated 
medications. This gap likely reflects an underappreciation of risk 
by both clinicians and patients and signifies a clear clinical ratio-
nale for the prognostic information troponin offers.
Although our findings are the first from a prospective obser-
vational cohort study, they are consistent with posthoc anal-
yses of randomised controlled trials of both stable coronary 
disease21 22 and recent myocardial infarction.10 11 These latter 
two studies include the Pravastatin or Atorvastatin Evaluation 
and Infection Therapy–Thrombolysis in Myocardial Infarction 
22 (PROVE-IT TIMI 22) trial of pravastatin following acute 
coronary syndrome, and the Examination of Cardiovascular 
Outcomes with Alogliptin versus Standard of Care (EXAMINE) 
trial, testing the cardiovascular safety of alogliptin in patients 
with type 2 diabetes mellitus. The prevalence of troponin 
concentrations >99th centile was 22.2% at 4 months in 
PROVE-IT TIMI 22% and 11.7% at 6 months in EXAMINE. 
Despite fewer overall events and shorter durations of follow-up, 
both studies identified strong associations between increasing 
troponin concentrations and cardiovascular risk. Interestingly, 
within the former study, troponin also appeared to identify 
those who derived greatest benefit from pravastatin, with an 
absolute risk reduction of 3.5% (95% CI 0.41 to 6.59) in the 
subset with high troponin concentrations compared with 0.4% 
(95% CI −1.0% to 0.9%) in the remainder. The use of troponin 
as a potentially useful target of therapeutic intervention has also 
previously been described in high-risk patients without estab-
lished coronary heart disease treated with statin therapy23 and 
the sodium glucose cotransporter 2 inhibitor canagliflozin,24 
where the reduction in troponin concentration on treatment was 
associated with the magnitude of cardiovascular benefit.
Taken alongside these reports, our study has important clinical 
implications regarding the measurement of troponin following 
an acute coronary syndrome. The American Heart Association 
estimates that 720 000 individuals within the USA alone will 
experience a first fatal or non-fatal myocardial infarction during 
2018.25 A further 335 000 will have a recurrent event.25 This 
sizeable residual risk persists despite major therapeutic advances 
including potent preventative therapies and early revascularisa-
tion. Improving long-term outcomes in a cost-effective manner 
will require improved therapeutic targeting. Within this context, 
troponin testing is inexpensive and already widely available in 
clinical practice. In the face of resource constraints, troponin 
concentrations could be used to guide the use of more costly 
investigations and in targeting treatments at the subgroup of 
patients identified to be at greatest risk of adverse events. We 
have shown that troponin concentrations increase as LVEF 
declines, and identifying this pattern could prompt clinicians to 
reassess cardiac function and encourage uptitration of risk modi-
fying drugs such as inhibitors of the renin-angiotensin system. 
Likewise, the relationship between increasing blood pressure 
and troponin reinforces the importance of optimisation of blood 
pressure-lowering therapies. Finally, troponin-guided care may 
have particular relevance when considering the appropriate 
use of novel therapeutic agents such as inhibitors of proprotein 
convertase subtilisin–kexin type 926 and the anti-inflammatory 
drug canakinumab.27 Accurate risk stratification may enable 
more rational use of these drugs which are expensive and asso-
ciated with potential adverse effects that may otherwise limit 
broad clinical application.
We recognise that our study has some limitations. The 
biomarker used for the index diagnosis of myocardial infarction 
varied between study centres and included the troponin T and 
troponin I assays available during the period of study recruit-
ment. This precludes a direct comparison of the relationship 
between the peak high-sensitivity troponin concentration and 
those measured using the high-sensitivity assay during follow-up. 
However, peak creatine kinase concentrations were available 
in 91% of patients and have previously been demonstrated to 
correlate with size of infarct and clinical outcomes.28 29 Using 
peak creatine kinase, we identified only a weak relationship with 
convalescent troponin values and no correlation with cardio-
vascular death within the fully adjusted model. This may reflect 
changes in contemporary management of the patients enrolled in 
Figure 4 Risk of cardiovascular death at 5 years according to 4-month 
troponin concentration and relative change in troponin concentration 
to 12 months. The estimated 5-year risk of cardiovascular death in 
relation to interval change in troponin concentrations is presented 
and grouped according to 4-month troponin concentrations (≤5 ng/L—
blue, 6 ng/L–99th centile—orange, >99th centile—red). The 95% CIs 
for these estimates are demonstrated within the correspondingly 
shaded regions. The rug-plot shown along the x-axis depicts each 
occurrence of the specific combination of 4-month troponin and 
relative change to 12 months within the study cohort. For descriptive 
purposes, troponin concentrations have been rounded to nearest 
integer value. Therefore, ≤5 ng/L includes all patients <5.5 ng/L. 
Additional details regarding this statistical model are provided in the 
online supplementary appendix. CVD, cardiovascular disease. 
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the CDCS with high rates of coronary revascularisation and use 
of secondary prevention medications. Finally, although analytical 
variation is modest, even at low concentrations, some variation 
in reported troponin concentrations is possible when testing is 
performed across different analysers and using different reagent 
batches. Such variation can be kept to a minimum through the 
careful application of quality control measures as recommended 
by current guidelines.30
We conclude that the measurement of high-sensitivity cardiac 
troponin in the convalescent phase following acute coronary 
syndrome identifies an important group of patients at high 
risk of recurrent cardiac events and death. Recognition of this 
increased risk may allow better targeting of secondary preven-
tion therapies and could improve the clinical impact of future 
therapeutic trials in patients with acute coronary syndrome.
Key messages
What is already known on this subject?
 ► In the diagnostic assessment of acute coronary syndromes, 
serial measurement of plasma cardiac troponin 
concentrations is recommended by European and North 
American guidelines. In this context, the detection of troponin 
concentrations above the 99th centile upper reference limit 
is associated with increased short-term risk and may help 
inform early management decisions regarding the need for 
hospital admission and inpatient coronary angiography. 
However, the prognostic value and optimal timing for 
measurement of convalescent troponin following hospital 
discharge remain unknown.
What might this study add?
 ► We investigated the long-term prognostic significance of 
serial convalescent high-sensitivity troponin I concentrations 
following acute coronary syndrome in a large prospective 
multicentre observational cohort study with detailed clinical, 
biochemical and echocardiographic characterisation. We 
identified a strong association between 4-month troponin 
concentrations and cardiovascular death over 5 years that 
was independent of the extent of myocardial injury during the 
index event and all other established risk factors. Repeated 
measurement of troponin at 12 months provided additional 
prognostic information.
how might this impact on clinical practice?
 ► Low plasma cardiac troponin I concentrations measured 
4 months following an index hospitalisation with acute 
coronary syndrome identified nearly half of all patients as 
being at very low risk of long-term cardiovascular death. In 
contrast, 1 in 10 patients have persistent myocardial injury 
and are at very high risk. These individuals clearly warrant 
close follow-up, with concerted efforts made to optimise their 
medical care. For the remaining intermediate-risk patients, 
repeated measurement of troponin concentrations at 12 
months enables prognostic reclassification into either low-
risk or high-risk groups.
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